Metastasis is the process through which tumor cells leave the initial tumour and travel throughout the body to establish a secondary tumour in other organs and anatomical sites. Tumor stem cells (CSC) are thought to be responsible for the aggressive and metastatic nature of triple-negative breast tumors (TNBC), and new therapeutic strategies are being devised to target them such as Flubendazole.
Bone, is one of the most preferential metastatic target sites for tumors. Prostate, lung, breast, kidney, and thyroid primary tumors account for 80% of skeletal metastases . Spine, pelvis, proximal femur, and skull are the most common sites of bone metastases.
Bone metastases can be divided into two broad categories; (i) osteolytic metastases that are associated with bone destruction and (ii) osteosclerotic metastases that are characterized by new bone formation. Bone metastases can be predominantly osteolytic or osteosclerotic, or mixed with features of both types .
BiohackIT METASTHIB™ is a broad-based nutraceutical formula containing herbal extracts and other nutrients which have been shown to reduce metastatic potential in particular it’s ability to migrate and establish in bone marrow and other body organs.
The key pathways the formula is targeting is RANKL (osteoclasts formation), Nf-kb(inflammation), TGF-beta(tumour cells invasiveness and angiogenesis), CXCR4 (invasiveness), VEGF (angiogenesis) and FAK (Focal Adhesion Kinase) which is involved in the regulation of cell migration and is elevated in states of emotional stress and flight or flight.
Growth factors and cytokines signalling pathways protect metastatic cells from anticancer drugs-induced apoptosis. Thus, targeting these survival factors in bone (TGFß, IGF, IL-6, FGF, RANKL and others) could increase cancer cells sensitivity to chemotherapeutic agents such as Flubendazole.
Receptor activator of NF-kappaB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival, and is blocked by a soluble decoy receptor, osteoprotegerin (OPG). In human malignancies that metastasize to bone, dysregulation of the RANK/RANKL/OPG pathway can increase the RANKL:OPG ratio, a condition which favors excessive osteolysis. The reduced OPG is caused by suppression of both constitutive OPG inducing cytokines TGF-ß and Wnt.
Clinical Studies Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796097/  In human malignancies that metastasize to bone, dysregulation of the RANK/RANKL/OPG pathway can increase the RANKL:OPG ratio, a condition which favors excessive osteolysis.
https://www.ncbi.nlm.nih.gov/pubmed/18064531  Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis
Quality Assurance Declaration
Werone.co endeavors to use the most potent source materials within our formulas. Our herbal extracts are sourced and tested by the only Government-certified large scale producer of crude herb (powder-free) TCM concentrates in Asia who manufacture to GMP / ISO 9001/2000 pharmaceutical grade and also operate an ISO17025/TAF-certified laboratory where they subject all plant extracts to strict quality inspections free from heavy metals, pesticides or microbes before release to the clinics all over the world. The formulas and tinctures are assembled without fillers in small batches by a BHMA member herbal dispensary.
Nutraceutical DisclaimerThese statements have not been evaluated by the Food and Drug Administration or MHRA and the items are not intended to diagnose, treat, cure, or prevent any disease nor are they associated, endorsed, affiliated or sponsored by Anthony William, Medical Medium® Joe Tippens, Jane McLelland or Jim Gordon.